News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Kristin Higgins, MD, City of Hope

Articles by Kristin Higgins, MD, City of Hope

Multidisciplinary Management of Patients With Stage III NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

Integrating Perioperative Immunotherapy Strategies in NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

Molecular testing in Patients With Metastatic NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

ADAURA: Osimertinib as Adjuvant Therapy in Stage III EGFR+ NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

Varied Timing of IO Therapy in Patients With Stage III NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

Treating for Stage III NSCLC After Progression on Durvalumab

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

Durvalumab in Stage III NSCLC Based on Performance Status

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

Mediastinal Staging in Non–Small Cell Lung Cancer

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

Latest Updated Articles

Integrating Perioperative Immunotherapy Strategies in NSCLC
Published: July 13th 2020 | Updated:
ADAURA: Osimertinib as Adjuvant Therapy in Stage III EGFR+ NSCLC
Published: July 13th 2020 | Updated:
Mediastinal Staging in Non–Small Cell Lung Cancer
Published: July 13th 2020 | Updated:
Treating for Stage III NSCLC After Progression on Durvalumab
Published: July 13th 2020 | Updated:
Varied Timing of IO Therapy in Patients With Stage III NSCLC
Published: July 13th 2020 | Updated:
Multidisciplinary Management of Patients With Stage III NSCLC
Published: July 13th 2020 | Updated:

Trending on OncLive

Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma

Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma